10:44 AM EDT, 05/01/2024 (MT Newswires) -- Merck ( MRK ) said Wednesday that a phase 3 trial assessing its cancer drug Keytruda showed positive results in overall survival for patients with advanced gastric cancer.
Merck ( MRK ) said Keytruda, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy, met its dual primary endpoint of overall survival in the trial.
The Keytruda drug combination showed "a statistically significant and clinically meaningful improvement" in overall survival compared to placebo, Merck ( MRK ) said.
Price: 129.03, Change: -0.19, Percent Change: -0.15